Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

13 May 2022 | Friday | News


Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announces that the Chinese Society of Clinical Oncology (CSCO), the most prominent medical society for oncology in China, has added multiple XPOVIO® (selinexor) regimens for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) to its 2022 Guidelines for the Diagnosis and Treatment of Hematologic Malignancies and 2022 Guidelines for the Diagnosis and Treatment of Lymphomas (CSCO Guidelines).
Image Source : Public Domain

Image Source : Public Domain

The 2022 CSCO Guidelines incorporate a total of four selinexor combination therapy regimens for relapsed myeloma. In addition, the guidelines also recommend the use of selinexor for the treatment of patients with ≥ twice relapsed/progressed DLBCL. As the gold standard guiding Chinese oncologists in their clinical practice, the CSCO Guidelines are one of the most recognized and widely adopted set of practice guidelines in China.  

Multiple Myeloma

Guideline for the treatment of relapsed myeloma

Evidence

Recommendation

selinexor plus bortezomib plus dexamethasone*

Class 1

Level I

selinexor plus pomalidomide plus dexamethasone

Class 2

Level II

selinexor plus daratumumab plus dexamethasone*

Class 2

Level II

selinexor plus carfilzomib plus dexamethasone*

Class 2

Level II

*newly included regimen

Incorporation of selinexor into the CSCO guidelines for R/R MM referenced data from the STORM and STOMP trials.

Prof. Wenming Chen, at Beijing Chao-Yang Hospital of Capital Medical University, said, "The continued development of novel therapies is key to improving treatment outcomes for patients with MM. Selinexor, the world's first oral selective XPO1 inhibitor, was granted an approval in China last year, and multiple selinexor regimens have been incorporated into practice guidelines by a number of leading medical societies/organizations. The recent recommendations of selinexor by the updated CSCO Guidelines for the Diagnosis and Treatment of Hematologic Malignancies indicates strong recognition of selinexor's safety and efficacy and is another validation of the robust clinical data supporting the wide clinical adoption of selinexor as a much-needed new treatment option. I hope more patients will soon benefit from this novel therapeutic."

Lymphoma

Guideline for the treatment of ≥ twice relapsed/progressed diffuse large B-cell lymphoma

Evidence

Recommendation

Selinexor monotherapy for third-line and subsequent therapy

Class 2A

Level II

Incorporation of selinexor into the CSCO guidelines for R/R DLBCL referenced data from the SADAL trial, the U.S. Food and Drug Administration's (FDA) approval and the National Cancer Care Network's (NCCN) guideline recommendations for selinexor in patients with R/R DLBCL.

Prof. Weili Zhao, at Ruijin Hospital of Shanghai Jiaotong University School of Medicine, commented, "Primary and secondary drug resistance and intolerance to standard of care therapies in a large portion of DLBCL patients pose a major clinical challenge, limiting the treatment outcomes and survival benefit for patients and resulting in the urgent need for a novel therapy with a new mechanism of action. Selinexor, a small molecule targeted therapy utilizing an innovative mechanism, is approved in the U.S. for the treatment of MM and DLBCL and has received regulatory approvals in various indications in a growing number of countries around the world. This inclusion of selinexor in the CSCO 2022 Guidelines for the Diagnosis and Treatment of Lymphomas presents a new treatment strategy for patients with ≥ twice relapsed/progressed DLBCL, and an important tool for clinicians seeking to change the current standard practices in DLBCL."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close